Curatis is a unique risk-balanced company, including a profitable and growing Specialty Distribution business and a Search & Development business with an emerging pipeline of products with peak sales ranging from USD 250-500 mn. Successful development and commercialization would be transformational.
Key catalysts include:
C-PTBE-01 - Apply for orphan & rare pediatric disease designation (H2 2024)
C-PTBE-01 - Scientific advice meeting FDA/EMA (H2 2024)
C-PTBE-01 - Partnering agreement (2025)